ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Dyne Therapeutics (DYN)
Dyne Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$16.63▲ +5.79%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Dyne Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Dyne Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Dyne Therapeutics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $14.78 and $18.33; in 9 out of 10, between $12.21 and $22.18. Estimated annual volatility is 59%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $3.0B
- 52-week high
- $27.31
- 52-week low
- $14.00
- Revenue (12 months)
- $0.0M
- Return on equity
- -81.6%
- Free cash flow (12 months)
- $-317M
- Beta
- 1.08
What this means
ATLAS does not publish a fair value for DYN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks DYN has traded between $14.00 and $27.31. Today it is 39.1% below that high and 19% above its low.
Its beta is 1.08: it moves roughly in line with the market.
About the company
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases.
Want to see everything about Dyne Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Dyne Therapeutics do?
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases.
What is the chance DYN goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, DYN ends the month between $14.78 and $18.33.
How big is Dyne Therapeutics and what is its P/E ratio?
Dyne Therapeutics's market capitalization is $3.0B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is DYN?
ATLAS estimates annual volatility at 59%. In a typical month, half of the outcomes end between $14.78 and $18.33.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer